arrow
A

Andrea M. Gross

National Cancer Institute
H指数:26
被引数:2,965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium

恶性外周神经鞘瘤临床试验中新型药物优先级评估框架:神经纤维瘤临床试验联盟的报告

2026-08-180
PRE
New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis

罕见病临床试验的新方法:神经纤维瘤病1型和施万瘤的分散式试验设计

Cancers
IF4.4
2026-08-010
OA
Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas

神经纤维瘤病1型患者在接受MEK抑制剂治疗plexiform神经纤维瘤时发生恶性周围神经鞘瘤的风险

2026-07-310
OA
Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series

MEK抑制剂治疗期间恶性周围神经鞘瘤的发展:一项预临床研究和临床病例系列

2026-07-110
OA
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment

携带RAS/MAPK基因致病变异成人的癌症风险:基于基因组确诊的研究

2026-03-250
PRE
Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception

罕见癌症研究:当前知识状态及预防与干预的涌现机遇

2026-03-100
PRE
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma

参与者在进行MEK抑制剂临床试验的丛状神经纤维瘤中致病性NF1变异的谱系

2025-10-150
PRE
Long-term Ocular Safety in Children Treated with MAPK Pathway Inhibitor Therapy

接受MAPK通路抑制剂治疗儿童的长期眼部安全性

2025-10-100
PRE
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib A Nonrandomized Clinical Trial

神经纤维瘤病1型皮肤神经纤维瘤的MEK抑制剂Selumetinib治疗:一项非随机临床试验

2025-02-260
PRE
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies
2024-08-281
PRE
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
2024-08-020
OAAI
snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response
2024-06-211
OAAI